FDA panel narrowly recommends authorization of first antiviral to treat COVID-19
The drug, molnupiravir from Merck, is intended to be used in people at risk for severe COVID-19. The FDA panel authorized its use by a vote of 13-10.
FDA panel narrowly recommends authorization of first antiviral to treat COVID-19
USATODAY.com
0 shares
1 views
- More about:
Food and Drug Administration- COVID-19
- Merck & Co.
You might like
Related news coverage
-
Alert: FDA health panel endorses Merck COVID-19 pill, paving way for U.S. authorization of the first at-home drug for virus
SeattlePI.com
-
FDA panel narrowly backs COVID-19 pill from Merck
Newsday
-
An FDA expert panel narrowly supports the first COVID-19 pill but suggests restrictions on its use driven by safety concerns
Business Insider
-
FDA advisers narrowly recommend authorization of first antiviral pill to treat covid-19
Washington Post
Advertisement
More coverage
FDA Reviewing Merck's COVID Pill For Emergency Authorization
Newsy
Watch VideoAn experimental COVID-19 drug that could soon become the first U.S.-authorized pill to treat the coronavirus faces one..
